Lantern Pharma INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Empery Asset Management, LP and Ryan M. Lane have filed a Schedule 13G, reporting beneficial ownership of 9.99% of Lantern Pharma Inc.'s common stock, including shares issuable from warrants.
NASDAQ
Thomas A. Satterfield, Jr. has reported beneficial ownership of 975,000 shares, representing 7.6% of Lantern Pharma Inc.'s common stock.
NASDAQ
Thomas A. Satterfield, Jr. has disclosed beneficial ownership of 570,000 shares, representing 5.1% of Lantern Pharma Inc.'s common stock, as of March 30, 2026.